Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

NCT03287414 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: VAY736
DRUG: Placebo
DRUG: Standard of Care (SoC)

Sponsor

Novartis Pharmaceuticals